Compare Stocks

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$0.88	$0.99	$0.65 ▼ $1.49	$360.82M	1.98	1.99 million shs	657,243 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	-0.53%	-4.20%	+4.11%	-30.27%	-31.36%

Will this $2 AI stock double overnight? (Ad)

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

Click here to learn more >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMRN Amarin	0.2035 of 5 stars	1.9	3.0	0.0	0.0	0.0	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.75	Reduce	$1.08	23.30% Upside

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$306.91M	1.18	N/A	N/A	$1.35 per share	0.65

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$59.11M	-$0.14	N/A	N/A	N/A	-19.26%	-10.47%	-6.97%	5/1/2024 (Confirmed)

Latest AMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/1/2024	N/A	AMRN Amarin	-$0.0350	N/A	+$0.0350	N/A	N/A	N/A
2/29/2024	Q4 2023	AMRN Amarin	-$0.05	-$0.01	+$0.04	-$0.01	$72.46 million	$74.71 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	2.80	1.80

Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	1.96%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	275	410.67 million	402.62 million	Optionable

AMRN Headlines

Source	Headline
	Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event finance.yahoo.com - April 24 at 4:47 PM
	Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event globenewswire.com - April 24 at 2:00 PM
	Amarin (AMRN) to Release Earnings on Wednesday americanbankingnews.com - April 24 at 5:16 AM
	Amarin Announces Results of Annual General Meeting of Shareholders globenewswire.com - April 22 at 8:00 AM
	Amarin Corporation: Small Signs Of Recovery May Not Be Enough seekingalpha.com - April 18 at 12:18 AM
	Amarin (NASDAQ:AMRN) Stock Price Passes Above Two Hundred Day Moving Average of $0.93 americanbankingnews.com - April 16 at 2:56 AM
	Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 globenewswire.com - April 15 at 8:00 AM
	Amarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups finanznachrichten.de - April 8 at 8:22 AM
	Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 globenewswire.com - April 8 at 8:00 AM
	New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups globenewswire.com - April 6 at 3:30 PM
	Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe zacks.com - April 4 at 2:21 PM
	Why Amarin Stock Was Rocketing Higher on Wednesday fool.com - April 3 at 4:13 PM
	Amarin: IP Protection For VAZKEPA In Europe Now Extended Into 2039 - Quick Facts markets.businessinsider.com - April 3 at 9:58 AM
	Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe globenewswire.com - April 3 at 8:00 AM
	Amarin Co. plc (NASDAQ:AMRN) Short Interest Update marketbeat.com - April 2 at 7:16 AM
	Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo finance.yahoo.com - March 25 at 7:36 PM
	Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo globenewswire.com - March 25 at 8:00 AM
	AMRN Apr 2024 3.000 call finance.yahoo.com - March 16 at 10:26 AM
	Gaysorn Amarin to create income boost bangkokpost.com - March 12 at 2:42 PM
	AMRN Apr 2024 1.500 put finance.yahoo.com - March 8 at 12:20 AM
	AMRN May 2024 1.000 call finance.yahoo.com - March 7 at 7:20 PM
	AMRN Mar 2024 0.500 call finance.yahoo.com - March 6 at 7:34 PM
	Amarin Full Year 2023 Earnings: Beats Expectations finance.yahoo.com - March 5 at 10:01 AM
	Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript seekingalpha.com - March 2 at 11:19 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Amarin

NASDAQ:AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial